Top 10 Companies in the 1(2H)-Phthalazinone Market (2026): Market Leaders Powering Global Pharmaceutical Innovation

MARKET INSIGHTS

Global 1(2H)-Phthalazinone market size was valued at USD 28.4 million in 2025. The market is projected to grow from USD 30.1 million in 2026 to USD 52.7 million by 2034, exhibiting a CAGR of 7.3% during the forecast period.

1(2H)-Phthalazinone is a heterocyclic organic compound belonging to the phthalazine family, characterized by a bicyclic structure consisting of a benzene ring fused with a pyridazinone ring. This compound serves as a critical building block and pharmacophore in medicinal chemistry, widely utilized in the synthesis of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and specialty fine chemicals. Its structural versatility makes it particularly valuable in the development of kinase inhibitors, anti‑inflammatory agents, and antitumor compounds.

The market is experiencing steady growth driven by rising demand from the pharmaceutical research and development sector, where 1(2H)-Phthalazinone derivatives are increasingly explored as scaffolds in drug discovery programs. Furthermore, the expanding pipeline of oncology and cardiovascular therapeutics incorporating phthalazinone‑based structures continues to support market momentum. Key manufacturers and fine chemical suppliers, including TCI Chemicals, Sigma‑Aldrich (Merck KGaA), and Alfa Aesar, maintain active portfolios of this compound to meet growing global research demand.

1(2H)-Phthalazinone Market – View in Detailed Research Report

Top 10 Companies in the 1(2H)-Phthalazinone Market

10️⃣ 1. MilliporeSigma (Sigma‑Aldrich)

Headquarters: Irving, Texas, USA / Darmstadt, Germany
Key Offering: Pharmaceutical‑grade 1(2H)-Phthalazinone, custom synthesis, analytical support

MilliporeSigma leverages its extensive global distribution network to deliver high‑purity intermediates to pharmaceutical and research clients. Its integrated quality management system ensures consistent batch‑to‑batch performance, a critical attribute for API development. The company has recently expanded its contract‑development services, enabling clients to outsource early‑stage synthesis and process optimisation.

Sustainability & Growth Initiatives:

• Investments in green chemistry pathways to reduce solvent use
• Enhanced waste‑management protocols aligned with REACH and RoHS requirements
• Collaborations with academic centres to validate new synthesis routes

9️⃣ 2. Alfa Aesar (Thermo Fisher Scientific)

Headquarters: Irving, Texas, USA
Key Offering: Research‑grade 1(2H)-Phthalazinone, bulk API intermediates, rapid‑turnover catalog

Alfa Aesar’s catalog‑grade inventory serves CROs and academic laboratories worldwide. The brand’s reputation for fast turnaround times and competitive pricing attracts early‑stage research projects that demand rapid access to heterocyclic building blocks. Recent product launches include a new high‑purity line tailored for kinase‑inhibitor libraries.

Sustainability & Growth Initiatives:

• Implementation of solvent‑free reaction protocols for selected intermediates
• Carbon‑neutral shipping options for high‑volume orders
• Partnerships with universities to co‑develop novel synthetic routes

8️⃣ 3. TCI Chemicals

Headquarters: Tokyo, Japan
Key Offering: Pharmaceutical‑grade 1(2H)-Phthalazinone, custom synthesis, analytical support

TCI Chemicals is recognised for its robust quality control infrastructure and rapid custom‑synthesis capabilities. The company’s focus on process‑scale‑up for API intermediates aligns with the needs of emerging biopharmaceutical firms seeking cost‑effective production routes.

Sustainability & Growth Initiatives:

• Development of catalytic cyclisation routes to minimise by‑product formation
• Investment in renewable feedstock sourcing for large‑scale batches
• Collaboration with Japanese regulatory bodies to streamline GMP certification

7️⃣ 4. Combi‑Blocks

Headquarters: New York, USA
Key Offering: Custom‑synthesis services, small‑to‑mid‑scale production, rapid prototyping

Combi‑Blocks differentiates itself through flexible order sizes and rapid prototyping for early‑stage drug discovery. Its modular synthesis platform allows chemists to explore a wide range of heterocyclic scaffolds, including 1(2H)-Phthalazinone, without committing to large‑scale production.

Sustainability & Growth Initiatives:

• Adoption of micro‑reactor technology to reduce solvent consumption
• Implementation of closed‑loop recycling for hydrazine by‑products
• Engagement with industry consortia to standardise safety protocols

6️⃣ 5. Fluorochem

Headquarters: London, United Kingdom
Key Offering: Specialty‑grade 1(2H)-Phthalazinone, fluorinated analogues, analytical support

Fluorochem supplies high‑purity intermediates to the pharmaceutical and agrochemical sectors, with a strong emphasis on fluorinated derivatives that enhance metabolic stability. The company’s analytical expertise supports rigorous quality assurance for clients operating under stringent GMP conditions.

Sustainability & Growth Initiatives:

• Development of low‑toxicity fluorination reagents
• Energy‑efficient reactor designs for large‑scale synthesis
• Participation in European green‑chemistry research programmes

5️⃣ 6. Hangzhou Keying Chem

Headquarters: Hangzhou, China
Key Offering: Cost‑effective 1(2H)-Phthalazinone, bulk production, custom synthesis

Hangzhou Keying Chem has scaled its production capacity to serve the growing generic pharmaceutical market in Asia. The company’s focus on cost‑efficiency and rapid delivery positions it as a preferred supplier for generic manufacturers seeking high‑quality intermediates at competitive prices.

Sustainability & Growth Initiatives:

• Implementation of waste‑water treatment upgrades to meet local environmental regulations
• Adoption of renewable energy sources for plant operations
• Collaboration with Chinese universities to advance green‑synthesis research

4️⃣ 7. Sinopharm Chemical Reagent

Headquarters: Shanghai, China
Key Offering: Pharmaceutical‑grade 1(2H)-Phthalazinone, bulk API intermediates, rapid custom synthesis

Sinopharm Chemical Reagent serves a broad client base that includes both domestic and international pharmaceutical companies. Its integrated quality assurance processes ensure compliance with international pharmacopeial standards, making it a reliable source for API development.

Sustainability & Growth Initiatives:

• Optimization of solvent‑recovery systems to reduce environmental footprint
• Investment in automated synthesis lines to enhance throughput
• Participation in national clean‑production initiatives

3️⃣ 8. Acros Organics

Headquarters: Brussels, Belgium
Key Offering: High‑purity 1(2H)-Phthalazinone, research‑grade catalog, analytical support

Acros Organics supplies a range of heterocyclic intermediates to research institutions and small‑to‑mid‑scale manufacturers. Its emphasis on stringent purity controls and detailed batch documentation caters to the needs of laboratories engaged in early‑stage drug discovery.

Sustainability & Growth Initiatives:

• Development of solvent‑free synthetic protocols for key intermediates
• Implementation of energy‑efficient heating systems across production facilities
• Collaboration with European regulatory bodies to streamline GMP compliance

2️⃣ 9. Merck KGaA

Headquarters: Darmstadt, Germany
Key Offering: Pharmaceutical‑grade 1(2H)-Phthalazinone, API development support, analytical services

Merck KGaA’s expertise in medicinal chemistry and large‑scale manufacturing positions it as a strategic partner for companies developing kinase inhibitors and PARP inhibitors. The firm’s integrated R&D and manufacturing capabilities enable seamless transition from laboratory synthesis to commercial production.

Sustainability & Growth Initiatives:

• Investment in catalytic processes that lower carbon footprint
• Adoption of digital process‑control systems for real‑time monitoring
• Engagement in European green‑chemistry consortiums to drive industry‑wide sustainability

1️⃣ 10. Thermo Fisher Scientific

Headquarters: Waltham, Massachusetts, USA
Key Offering: Comprehensive supply of 1(2H)-Phthalazinone, custom synthesis, analytical instrumentation

Thermo Fisher Scientific combines a vast product portfolio with advanced analytical instrumentation, offering clients end‑to‑end solutions for pharmaceutical development. Its global service network and commitment to quality support clients in meeting regulatory requirements across multiple regions.

Sustainability & Growth Initiatives:

• Expansion of renewable‑energy‑powered manufacturing sites
• Development of low‑toxicity reagent alternatives for heterocyclic synthesis
• Partnerships with universities to pilot next‑generation green‑chemistry technologies

Download FREE Sample Report

Get Full Report

Outlook: The Future of 1(2H)-Phthalazinone Market

The 1(2H)-Phthalazinone market is poised to maintain a steady trajectory as pharmaceutical companies continue to prioritise small‑molecule discovery and targeted oncology therapies. The expanding pipeline of kinase inhibitors and PARP inhibitors will sustain demand for high‑purity intermediates, while the rise of contract‑development organisations will drive custom‑synthesis services. Regulatory emphasis on quality and safety will shape production practices, encouraging the adoption of green‑chemistry approaches that reduce waste and lower operational costs.

Future Trends Shaping the Market

• Kinase‑Inhibitor Development: The integration of 1(2H)-Phthalazinone into novel kinase‑inhibitor scaffolds will continue to push demand for high‑purity intermediates.
• PARP‑Inhibitor Expansion: New indications for PARP inhibitors, including non‑BRCA‑mutated cancers, will broaden the therapeutic landscape and increase raw‑material consumption.
• Anti‑Inflammatory and Anti‑Infective Applications: Early‑stage research into phthalazinone derivatives for inflammatory and infectious diseases suggests potential future growth beyond oncology.
• Central Nervous System (CNS) Targets: Structural modifications that enhance blood‑brain barrier permeability are generating interest in CNS‑active compounds, offering a new avenue for market expansion.
• Green Chemistry Adoption: The push for solvent‑free and renewable‑feedstock synthesis will drive process innovation, lowering environmental impact and potentially reducing cost per kilogram.
• Regulatory Alignment: Harmonised GMP and safety standards across regions will streamline supply chains, enabling manufacturers to scale production more efficiently.
• Digitalisation of Supply Chains: Real‑time tracking and data‑driven quality management will improve transparency and reduce lead times for end‑users.